Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11114168 | 0.84 | CA2 (0.33) | CA2 | |
| SCHEMBL28595771 | 0.84 | CA2 (0.33) | CA2 | |
| SCHEMBL12523006 | 0.80 | CA2 (0.30) | CA2 | |
| SCHEMBL8910610 | 0.74 | CA2 (0.32) | CA2 | |
| SCHEMBL12540514 | 0.74 | CA2 (0.32) | CA2 | |
| SCHEMBL4248034 | 0.74 | CA2 (0.32) | CA2 | |
| SCHEMBL16371103 | 0.74 | CA2 (0.32) | CA2 | |
| SCHEMBL14107378 | 0.74 | CA2 (0.32) | CA2 | |
| SCHEMBL11961355 | 0.74 | CA2 (0.32) | CA2 | |
| SCHEMBL4248027 | 0.74 | CA2 (0.32) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073897-B2 | Cyclic sulfonium salt, process for production of same, and α-glucosidase inhibitor comprising same | KINKI UNIVERSITY (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9073897-B2 | Cyclic sulfonium salt, process for production of same, and α-glucosidase inhibitor comprising same | KINKI UNIVERSITY (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20140031394-A1 | CYCLIC SULFONIUM SALT, PROCESS FOR PRODUCTION OF SAME, AND alpha-GLUCOSIDASE INHIBITOR COMPRISING SAME | DIABETYM CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-20140031394-A1 | CYCLIC SULFONIUM SALT, PROCESS FOR PRODUCTION OF SAME, AND alpha-GLUCOSIDASE INHIBITOR COMPRISING SAME | DIABETYM CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031394-A1 | CYCLIC SULFONIUM SALT, PROCESS FOR PRODUCTION OF SAME, AND alpha-GLUCOSIDASE INHIBITOR COMPRISING SAME | SI, GANAB, GANC | CA2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.